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Abstract
CITED2 is a transcriptional co-activator with 3 conserved domains shared with other CITED family members and a unique
Serine-Glycine Rich Junction (SRJ) that is highly conserved in placental mammals. Loss of Cited2 in mice results in cardiac
and aortic arch malformations, adrenal agenesis, neural tube and placental defects, and partially penetrant defects in left-
right patterning. By screening 1126 sporadic congenital heart disease (CHD) cases and 1227 controls, we identified 19
variants, including 5 unique non-synonymous sequence variations (N62S, R92G, T166N, G180-A187del and A187T) in
patients. Many of the CHD-specific variants identified in this and previous studies cluster in the SRJ domain. Transient
transfection experiments show that T166N mutation impairs TFAP2 co-activation function and ES cell proliferation. We find
that CITED2 is phosphorylated by MAPK1 in vitro at T166, and that MAPK1 activation enhances the coactivation function of
CITED2 but not of CITED2-T166N. In order to investigate the functional significance in vivo, we generated a T166N mutation
of mouse Cited2. We also used PhiC31 integrase-mediated cassette exchange to generate a Cited2 knock-in allele replacing
the mouse Cited2 coding sequence with human CITED2 and with a mutant form deleting the entire SRJ domain. Mouse
embryos expressing only CITED2-T166N or CITED2-SRJ-deleted alleles surprisingly show no morphological abnormalities,
and mice are viable and fertile. These results indicate that the SRJ domain is dispensable for these functions of CITED2 in
mice and that mutations clustering in the SRJ region are unlikely to be the sole cause of the malformations observed in
patients with sporadic CHD. Our results also suggest that coding sequence mutations observed in case-control studies need
validation using in vivo models and that predictions based on structural conservation and in vitro functional assays, or even
in vivo global loss of function models, may be insufficient.
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Introduction
Congenital heart disease (CHD) is one of the major causes of
childhood morbidity and mortality in the West. The incidence of
CHD in live-born infants ranges from 0.4 to 1.2% [1,2], and
increases in first-degree relatives to 2–5% [2], suggesting a role for
genetic or environmental variations which may contribute to
disease risk. Chromosomal and Mendelian syndromes account for
approximately 20% (11.9% and 7.4% respectively) of CHD cases
[3,4]. The genetic architecture underlying the remaining 80% of
‘‘sporadic’’ CHD remains elusive and cannot be addressed by
standard family based linkage studies. However, genetic variants
have been shown to be associated with sporadic, non-Mendelian/
non-chromosomal CHD as non-synonymous disease-associated
mutations have previously been found in case-control studies [5].
CITED2 is a CREBBP/EP300-interacting protein that is
present in all vertebrates. It is highly conserved in placental
mammals, with 95% identity between human and mouse. It has
three regions (CR1-3) that are conserved in other CITED family
members, and also an unusual Serine-glycine Rich Junction (SRJ,
residues 161–199), which is unique to CITED2 [6–10]. The
function of CR2 (residues 215–270) is to bind the CH1 domain of
CREBBP and EP300 transcriptional co-activators, and in vitro
studies indicate that it is necessary for all known biological
activities of CITED2 [10–13]. CITED2 competitively inhibits
hypoxia-activated gene transcription by blocking the interaction
between CREBBP/EP300 and HIF-1A [10]. CITED2 also
functions as a transcriptional co-activator, by recruiting
CREBBP/EP300 to chromatin via the DNA-binding transcription
factor AP2 (TFAP2) [11,14,15]. The functions of CR1, CR3 and
the SRJ domain are not known. The SRJ domain has been
hypothesized to be a mutational hotspot as variants clustering in
this region have previously been reported in patients with CHD
[16,17].
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Cited2 is essential for normal mouse development. Mice lacking
Cited2 die in utero with cardiac and aortic arch malformations,
adrenal gland agenesis, small cranial and dorsal root ganglia,
exencephaly, and neural crest and left-right patterning defects
[11,15,18–22]. The cardiac malformations in mice lacking Cited2
are diverse and include atrial and ventricular septal defects, double
outlet right ventricle, common arterial trunk, tetralogy of Fallot,
transposition of the great arteries, and interrupted and aberrant
aortic arches.
In this study, we have investigated the involvement of CITED2
in CHD by direct sequencing of a cohort of CHD patients and
controls and confirmed the clustering of non-synonymous
mutations to the SRJ domain. In vitro experiments indicated that
a specific residue in the SRJ domain (T166) was a functional target
of MAPK1, and was necessary for TFAP2 co-activation. We used
gene-targeting technologies in the mouse to functionally assess the
contribution of T166 and the SRJ domain, as a whole, to disease.
Mouse embryos expressing only CITED2-T166N or CITED2
SRJ-deleted alleles surprisingly showed no structural abnormalities
by magnetic resonance imaging, and mice were viable and fertile.
These results suggest that the SRJ domain is dispensable for
CITED2 function in mice. Thus, point mutations and deletions
clustering in the SRJ region are unlikely to be the sole cause of the
malformations observed in patients with sporadic CHD, and may
require additional factors to cause disease.
Results
Rare variants are infrequently found in CITED2 in CHD
and cluster in the SRJ domain
We sequenced the entire CITED2 open reading frame in 1126
CHD cases and 1227 ethnically matched controls (Table 1 and
Table S1). Nineteen sequence variants were identified. Of the non-
synonymous variants found, five (T166N, R92G, N62S, A187T
and G180-A187del) were unique to cases, while two (P36R,
Q40H) were present only in controls. Three non-synonymous
variants (H39del, H160L, G194-G195del) were present in both
cases and controls. Three of the five non-synonymous variants
found only in cases were inherited from unaffected parents (N62S,
T166N and G180-A187del). Although there was an excess of non-
synonymous variants that were unique to cases, this was not
statistically significant using a 2-tailed Fisher’s exact test. H39del
was found in 10 cases and 1 control; however, we were unable to
confirm this ratio in a replicate cohort (9/566 in cases vs. 43/2394
in controls, p = n.s., Text S1).
Three of the five non-synonymous variants identified uniquely
in cases in this study, three of six in the study by Sperling et al. [16]
and four of four in the study by Yang et al. [17], lie within the SRJ
region of CITED2 (Fig. 1A). The SRJ domain is highly conserved
in placental mammals. It is, however, substantially abbreviated in
marsupials and is absent in other vertebrates (Fig. 1B). Using the
RONN program [23], we find that the SRJ domain is predicted to
have a highly disordered secondary structure. However, none of
the SRJ domain mutations listed above affected the disorder plot
to any significant extent (Fig. S1). A number of functions have
been indicated for intrinsically disordered regions, including
molecular recognition, ligand binding, protein, DNA and RNA
interactions, and as flexible linkers between domains [24].
CITED2 T166N mutation ablates TFAP2 coactivation
function in vitro
Using the program NetPhos, we found that T166 is predicted to
be a phosphorylation site for proline directed kinases [25,26]. The
T166N mutation is predicted to abolish this putative phosphor-
ylation site. To assess the functional significance of the T166N
variant we examined its ability to co-activate a TFAP2 isoform.
We performed transient transfection assays in Hep3B cells using a
TFAP2 luciferase reporter containing three copies of the human
metallothionein IIa TFAP2-binding site [11,14]. As reported
previously [11,14], transfection of CITED2 alone did not affect
reporter activity, and co-transfection of TFAP2C and CITED2,
enhanced reporter activity 2 fold over that achieved with TFAP2C
alone. In comparison, CITED2-T166N was severely defective for
TFAP2C co-activation (Fig. 2).
Another molecular function of CITED2 is to represses HIF1
transactivation by interfering with the interaction between the
carboxy-terminus of HIF1A, and EP300/CREBBP [10,27,28].
We tested the ability of CITED2 to repress the trans-activation of
a fusion protein that contains the yeast GAL4 DNA-binding
domain fused to the carboxy-terminus transactivation domain of
HIF1A (residues 723–826, GAL4-HIF1A [10]). This is a weak
transactivator under normoxic conditions but is strongly activated
by either hypoxia or the iron chelator desferrioxamine (DFO) [10].
We found that T166N was identical to wild-type CITED2 in
repressing GAL4-HIF1A transactivation. We also found that
CITED2-T166N is expressed at wild-type levels, binds EP300 and
TFAP2 efficiently in vitro, and is localised to the nucleus thus
Table 1. Synonymous and non-synonymous mutations
identified through direct sequencing of 1126 cases with CHD
and 1227 controls.
Variation Protein Cases Controls Diagnosis
Non-Synonymous, Unique
c.559G.A p.Ala187Thr 1 0 PS
c.497C.A p.Thr166Asn 1 0 TGA
c.274A.G p.Arg92Gly 1 0 ASD
c.185A.G p.Asn62Ser 1 0 TOF
c.538-561del p.Gly180_Ala187del 1 0 AVSD
c.107C.G p.Pro36Arg 0 1 Control
c.120G.C p.Gln40His 0 1 Control
Synonymous, Unique
c.762T.C p.Asp254Asp 1 0 Ebstein,VSD
c.612C.T p.Ser204Ser 1 0 TGA
c.471C.T p.Asn157Asn 1 0 ASD
c.381C.T p.His127His 1 0 TOF
c.276G.A p.Arg92Arg 1 0 VSD
c.117C.T p.His39His 0 1 Control
c.120G.A p.Gln40Gln 0 1 Control
Both
c.115-117delCAC p.His39del 10 1
c.479A.T p.His160Leu 11 9
c.582C.T p.Gly194Gly 7 13
c.21C.A p.Ala7Ala 306 336
c.580-
585delGGCGGC
p.Gly194_Gly195del 6 10
5 unique non-synonymous variants are observed in the cases and 2 in the
control group. Abbreviations: PS, pulmonic stenosis; TGA, transposition of great
arteries; ASD, atrial septal defect; TOF, Tetralogy of Fallot; AVSD, atrioventricular
septal defect; VSD, ventricular septal defect.
doi:10.1371/journal.pone.0046256.t001
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excluding these factors as possible mechanisms for impaired
function (Fig. S2).
CITED2 is phosphorylated by MAPK1 at S85, T166 and
T175
We examined the phosphorylation of CITED2 by MAPK1
(ERK2, Fig. 3). Recombinant human CITED2 was phosphory-
lated in vitro by active MAPK1. The phosphorylated CITED2 was
then digested with trypsin and the resulting peptides were
chromatographed on a Vydac C18 column. Three major peaks
of 32P radioactivity, termed A1 to A3, were observed. Both peaks
A1 and A2 contained a peptide corresponding to residues 71–92 of
CITED2 phosphorylated at Ser85. Interestingly, CITED2-Ser85
is not followed by a proline residue. Although all MAP Kinases
phosphorylate preferentially Ser or Thr followed by Pro, non-
canonical phosphorylation sites, such as the one found in
CITED2, have previously been shown [29–32]. No mass
spectrometry data was obtainable for the A3 group of peaks but
phosphoaminoacid analysis indicated that only phosphoThreonine
was present (data not shown). In addition, Edman degradation
showed the presence of 32P at residues 7 and 16. Only one tryptic
peptide occurs in CITED2 that is consistent with tryptic cleavage
at Lys/Arg followed by Threonine residues at positions 7 and 16
and it consists of residues 160–239,
(k)hsggsstpggsggsstpggsgsssgggagssnsgggsgsgnmpasvahvpaamlppn-
vidtdfideevlmslviemgldr. Varying oxidation states of the 4
Methionine residues in this sequence could account for its
complexity on the HPLC elution profile. Taken together, it
suggests that peak A3 is a mixture of peaks of 32P radioactivity
containing a diphosphopeptide corresponding to residues 160–239
phosphorylated at Thr166 and Thr175 (three minor peaks of
radioactivity were also observed eluting at 25–40 min, but the
identity of the phosphorylated residue(s) eluting in them could not
be determined). Phosphorylation of the mutant CITED2-T166N
Figure 1. Structure of CITED2. (A) Schematic diagram of human CITED2 showing conserved regions (CR) 1–3 and the serine-glycine rich junction
(SRJ). Also indicated are the locations of CITED2 variants. All unique non-synonymous variants found in this study are shown above the figure with
variants found in the SRJ highlighted. Unique non-synonymous variants found by Sperling et al., 2005 (*) and Yang et al., 2010 (+) are shown below.
SRJ comprises AA 161 to 199. (B) The CITED2 peptide sequence is shown for Homo sapiens (Human, HSCITED2, AF129290), CITED2-MRG1 (Human,
HSCITED2 MRG1 isoform lacking the entire SRJ), Pan troglodytes (Chimapanzee, PTCITED2), Nomascus leucogenys (Gibbon, NLCITED2), Loxodonta
africana (Elephant, LACITED2), Sus scrofa (Pig, SSCITED2), Bos taurus, (Cow, BTCITED2), Canis familiaris (Dog, CFCITED2), Mus musculus (Mouse,
MMCITED2), Rattus norvegicus (Rat, RNCITED2), Monodelphis domestica (Opossum, MDCITED2), Gallus gallus (Chicken, GGCITED2), Anolis carolinensis
(Anole lizard, ACCITED2), Xenopus laevis (African clawed frog, XLCITED2), Xenopus tropicalis (Western clawed frog, XTCITED2), and Danio rerio
(Zebrafish, DRCITED2). Sequence alignments taken from the latest genome builds from EBI Ensembl. SRJ domain spans region marked with grey bar
above corresponding to AA161 to 199 in the human protein sequence.
doi:10.1371/journal.pone.0046256.g001
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by MAPK1 was also analyzed by chromatography on a Vydac
C18 column after tryptic digestion. The same three major (called
A4 to A6 in the Fig. 3) and minor peptides phosphorylated on wild
type CITED2 were phosphorylated in CITED2-T166N, however,
the radioactivity of peak A3 was significantly reduced in the
mutant and some other minor peaks appeared (85–95 min on the
elution profile). Peaks A4 and A5 contained the peptide (residues
71–92) of CITED2 phosphorylated at Ser85. Peak A6 contained a
peptide with 32P radioactivity released at cycle 16 and containing
phospho-Thr (phosphoaminoacid analysis and Edman degrada-
tion, data not shown). On the basis of its similar HPLC elution
profile to peak A3 of wild type CITED2, this is most likely the
peptide containing residues 160–239 phosphorylated at Thr175.
The diphosphopeptide with phosphoThr166 was not found due to
the T166N mutation.
CITED2 coactivation is enhanced by activation of MAPK1
and requires T166
The above results suggested that CITED2 phosphorylation by
MAPK1 at T166 may be required for its coactivation function. To
test this, we performed coactivation studies in Hep3B cells. Here,
we co-transfected a TFAP2 reporter plasmid, and plasmids
encoding CITED2, CITED2T166N, MAPK1, and variants of
the MAPK1-activating kinase, MAPKK1S221A (a constitutively
inactive mutant) or MAPKK1-S217ES221E (a constitutively
active mutant). No significant effect of MAPK1 and MAPKK1
plasmids was observed on activity of the reporter in the absence of
TFAP2 (not shown) (Fig. 4). However a major effect (3-fold over
CITED2 alone) was observed on TFAP2C coactivation by
CITED2 in the presence of MAPK1+MAPKK1-S217ES221E.
In comparison to TFAP2C without CITED2, this represents a ,6
fold activation of the reporter (Fig. 4). Co-expression of MAPK1 or
MAPKK1 did not affect the expression of CITED2 (Fig. S3).
CITED2-T166N did not respond to MAPK1 activation. These
results indicate that activated MAPK1 enhances co-activation
function of CITED2 (Fig. 4). The effect is specific to TFAP2C in
these experiments, and also requires the T166 residue. Taken
together these results support the idea that T166 is the target of a
proline-directed kinase, and its phosphorylation enhances CIT-
ED2 coactivation function.
T166 is essential for maintaining ES proliferation in the
absence of Leukemia Inhibitory Factor (LIF)
We next sought to determine if T166 is necessary for the ability
of CITED2 to maintain mouse embryonic stem (ES) cell
proliferation. ES cells can proliferate indefinitely in culture, and
are pluripotent [33]. In mouse ES cells this requires the growth
factors LIF and BMP [34] and is correlated with the expression of
alkaline phosphatase [35]. Gain-of-function experiments have
shown that Nanog and Cited2 can bypass the requirement for LIF in
mouse ES cells [35–37]. We used a previously described episomal
expression system in ES cells for these experiments [36]. We
transfected plasmids bearing Nanog, CITED2, CITED2-T166N,
and empty vector controls in E14/T ES cells. Following
puromycin selection, cells were plated in the absence of LIF,
and numbers estimated using crystal violet staining at daily
intervals thereafter. These experiments showed that both Nanog
and CITED2 maintained the proliferation of ES cells in the
absence of LIF, whereas empty vector did not. CITED2-T166N
had a markedly reduced ability to maintain ES cell proliferation in
the absence of LIF suggesting that T166 is essential for
maintaining ES proliferation in the absence of LIF (Fig. 5).
Generation of mice harboring the non-synonymous
T166N variant within the Cited2 SRJ domain
In order to investigate the functional significance of the T166N
variant in vivo, the orthologous amino acid change was introduced
into the mouse Cited2 locus using homologous recombination in ES
cells (Fig. 6A). Cited2 +/T166N embryos (n= 9) and Cited2 T166N/T166N
embryos (n= 2) at 15.5 days post coitum (dpc) analyzed by magnetic
resonance imaging (MRI) were found to be anatomically normal,
showing no dominant effect. In addition, they were viable and
fertile. One possibility in the human situation is that the wild-type
allele may not sufficiently compensate for lack of activity of the
mutant allele. To determine if a single allele of Cited2 T166N would
support normal embryonic development, we studied Cited2 2/T166N
mouse embryos. Cited2 2/T166N mice were generated by crossing
Cited2 +/T166N to Cited2 +/2. 31 out of 31 Cited2 2/T166N mouse
embryos at 15.5 days post coitum (dpc) analyzed by magnetic
resonance imaging (MRI) were found to be anatomically normal.
They revealed none of the structural developmental anomalies
associated with the loss of Cited2 and had normal sized adrenal
glands (Fig. 7C, H and M, Fig. S4). Furthermore, Cited2 2/T166N
mice were born at the expected Mendelian ratios (6/20, Table 2A,
X2(3)=0.4; p=n.s.) and were viable and fertile.
Development of a system to efficiently introduce human
CITED2 variants into mouse Cited2
In order to introduce human CITED2 variants into the mouse
Cited2 gene at high efficiency, we adapted a Recombinase
Mediated Cassette Exchange (RMCE) system that uses PhiC31
integrase [38,39]. Using homologous recombination, the Cited2
gene was targeted in C57BL/6N mouse ES cells so that exon 2
(which contains the entire open reading frame, ORF) became
flanked with attP sites, resulting in the generation of ES cell line,
Cited2 attP (Fig. 6B). Using this ES cell line, the Cited2 ORF can be
manipulated and exchanged with sequences introduced using the
exchange plasmids harboring analogously positioned attB sites. Co-
transfection with PhiC31 integrase results in their stable integra-
tion at high efficiency within the Cited2 gene (data not shown).
Generation of mice lacking the CITED2 SRJ domain
As variants found in patients tend to cluster in the SRJ domain,
and having found that a non-synonymous mutation within the SRJ
Figure 2. CITED2 mutation and its functional consequences.
Hep3B cells were transiently transfected with the 3xAP2-luciferase
reporter and the indicated plasmids and with CMV-lacZ. Results
(mean6SEM, three independent experiments) are presented as relative
luciferase units (RLU), corrected for b-galactosidase activity. The control
transfection value (at the extreme left) in each case (with CMV-vector) is
set at 1.
doi:10.1371/journal.pone.0046256.g002
Mutations in CITED2
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domain was compatible with normal embryonic development, we
sought to understand the function of the SRJ domain as a whole by
assessing the effect of replacing the mouse Cited2 ORF with that of
the human CITED2 MRG1 isoform [6,7]. This isoform lacks
residues 158–214 (i.e. the SRJ region plus 18 flanking amino acids)
and is a rare variant of CITED2 (ENSP00000376126, Fig. 1B)
which likely arises from non-canonical splice sites within exon 2
[10]. In order to achieve this, the endogenous mouse Cited2ORF in
Cited2 attP ES cells was replaced using RMCEwith the CITED2 MRG1
ORF (referred to as Cited2 MRG1) and its corresponding control, full-
length human CITED2 ORF (referred to as Cited2 HUM, Fig. 6C).
The SRJ domain of CITED2 is dispensable for function
Cited2 2/MRG1 embryos, generated by crossing Cited2 +/MRG1 to
Cited2 +/2mice, were devoid of wild type Cited2 and expressed only a
single copy of the CITED2-MRG1 isoform. This was confirmed by
western blotting and by Reverse Transcription Polymerase Chain
Reaction (RT-PCR) followed by sequencing of the PCR products
(Fig. 8A and B). 74 of 75 Cited2 2/MRG1 embryos harvested at
15.5 dpc and analyzed using MRI showed no overt cardiac or other
anatomical developmental anomalies associated with loss of Cited2,
and they all showed normal sized adrenal glands (Fig. 7D, I and N
and Fig. S4). One embryo presented with ectopia cordis, small
ventricular septal defect, oedema and other structural anomalies
(Fig. S5). Cited2 2/MRG1 and Cited2 MRG1/MRG1mice were found to be
viable and fertile. Furthermore, Cited2 2/MRG1 mice were found at
the expected Mendelian ratio at weaning (12/41, Table 2B, X2 (3):
0.46, p=n.s.). The same analysis was carried out for the control, full
length Cited2 HUM allele. No anatomical anomalies were found in
Cited2 2/HUM embryos (0/20). Cited2 HUM/HUMmice were also viable
and fertile as were Cited2 2/HUM (data not shown).
Discussion
Our resequencing study reported here and those reported
elsewhere [16,17] indicate that non-synonymous mutations of
CITED2 can be observed in patients with congenital heart disease,
and that these mutations tend to cluster in the SRJ domain. Cell-
based assays investigating some of these variants have indicated
that they can affect HIF1A-repression and/or TFAP2-coactivation
Figure 3. Identification of residues in CITED2 wild type or CITED2T166N phosphorylated by ERK2 (MAPK1). (A) GST-CITED2 wild type
or mutant GST-CITED2T166N were incubated with Mg [32P]ATP in the presence of ERK2 and subjected to SDS-PAGE. The phosphorylated CITED2 was
excised from the gel, digested with trypsin and the peptide separated by chromatography on a Vydac C18 column. The column was developed with
an acetonitrile gradient (broken line) and 32P-radioactivity is shown (full line). The phosphopeptides A1 to A6 are indicated. (B) The major peaks (A1 to
A6) of 32P-radioactivity were analysed by MALDI-TOF, MALDI TOF-TOF, Edman degradation and phosphoamino acid analysis as described in Materials
and Methods and the data for A1–A3 is shown. The sequence inferred from this data is shown underneath each figure.
doi:10.1371/journal.pone.0046256.g003
Mutations in CITED2
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functions of CITED2 [16]. The SRJ domain, although highly
conserved in placental mammals, is substantially abbreviated in
marsupials (e.g. the opossum Monodelphys domesticus) and in
monotremes (e.g. the platypus Ornithorhynchus anatinus), and is
absent in other vertebrates (Fig. 1B). Thus, the region may have
appeared relatively recently in evolutionary terms and may
conceivably be of relevance to differences in cardiac development
and structure between placental mammals and other vertebrates
[40–43].
Structurally, the SRJ region is predicted to be disordered and
potentially functions as a flexible linker [24]. The T166 residue
within this domain is predicted to be a target of proline directed
kinases [25,26], and our studies indicated that the T166 residue
can be phosphorylated by MAPK1, and that activation of MAPK1
promoted co-activation function. Moreover cell-based studies
indicated that the T166N mutation had a deleterious effect on
TFAP2 co-activation function, and on the ability of CITED2 to
promote ES cell proliferation in the absence of LIF.
Surprisingly, our in vivo study of mice carrying the T166N
variant and the deletion of the SRJ domain indicate that in mice,
under normal laboratory conditions, neither the complete deletion
of the SRJ domain nor the introduction of a variant which could
potentially lead to the loss of a phosphorylation site of CITED2
are detrimental to its function. In a single Cited2 2/MRG1 embryo
out of 75 that we studied, we observed an ectopia cordis
phenotype. Since ectopia cordis is not a phenotype which has
previously been associated with the loss of Cited2
[11,15,17,21,22,44–47], and this embryo has normal adrenal
glands (absence of which is a hallmark of Cited2 deficiency), it is
most unlikely that it is a consequence of the loss of the SRJ
domain. Animals of this genotype are also viable and fertile.
However, in vitro data indicate that the T166N mutation can have
functional significance, and previous studies have indicated that
other SRJ mutations also affect its function [16]. It is possible that
the partial impairment of CITED2 function revealed by in vitro
experiments is insufficient to affect development.
Taken together, the results obtained from mouse studies
indicate that the SRJ domain is dispensable during mouse cardiac
development and for viability and fertility. On the other hand,
three independent human studies show that non-synonymous
mutations, predominantly clustering in the SRJ domain, are
mainly observed in patients with CHD and not in controls
suggesting that this region is important for normal cardiac
development. How can we explain these divergent observations?
One possibility is that the SRJ is indeed dispensable for
mammalian heart development, and that the observations from
patients may be misleading. Supporting this idea, there is
considerable lack of conservation in this domain between placental
and non-placental mammals. Furthermore, the mutations in the
SRJ do not significantly affect the disordered nature of the
domain, indicating that it may be able to accommodate mutations
without adversely affecting the overall structure and function of
the protein. Moreover, in no case has it been shown that the
mutation has either arisen de novo or been transmitted from an
affected parent. Another possibility that partially reconciles the
mouse and human observations is that variants found clustered in
the SRJ in CHD patients may not, by themselves, be causative of
disease and may require additional factors, such as second site
genetic modifiers or environmental stress, for a phenotypic
manifestation. Supporting this idea, we have previously shown
that a maternal high-fat diet can alter the penetrance of left-right
patterning defects and cleft palate in Cited2 deficient mouse
embryos [48]. In addition, we have also shown that Cited2 can
genetically interact with other developmental genes: loss of Lmo4
can affect the Cited2 phenotype [49]. A third possibility to be
considered is human and mouse discordance where the mouse
model fails to phenocopy the human disease. For instance,
mutations in EVC and DHCR7 result in heart defects in humans
(Ellis van Creveld Syndrome, OMIM 225500, Smith-Lemli-Opitz
syndrome OMIM 270400) but not in the mouse [33,50,51].
To summarise, using a case-control approach we found, like
others, that non-synonymous variants cluster in the SRJ region of
CITED2 in CHD patients but not in controls. A point mutation
(T166N) in this region greatly affects CITED2 co-activation
function and LIF-independent growth of ES cells and is likely
phosphorylated by MAPK1. We found that mice harboring, either
the T166N point mutation or a deletion of the entire SRJ domain
and 18 adjacent amino acids, undergo normal cardiac develop-
Figure 4. MAPK signalling to CITED2 enhances its co-activation
function. Hep3B cells were transiently transfected with the 3xAP2-
luciferase reporter, with CMV-lacZ, CITED2-expressing plasmid or the
control vector and plasmids expressing MAPK1 or the control vector
and with plasmids expressing a defective MAPKK1 (SV40-MAPKK1-
S221A) or a constitutively active MAPKK1 (SV40-MAPKK1-S217ES221E).
Results are presented as relative luciferase units corrected for lacZ
activity. The control transfection value (at the extreme left) in each case
(with CMV-vector) is set at 1.
doi:10.1371/journal.pone.0046256.g004
Figure 5. ES cell proliferation rescue by wild-type CITED2 and
CITED2-T166N in the absence of leukemia inhibitory factor
(LIF). E14/T ES cells transfected by electroporation with the indicated
plasmids were selected in puromycin. Surviving cells were plated in
quadruplicate into 12-well plates in medium containing puromycin, but
in the absence of LIF. The cells were fixed at the indicated time points
using 10% formalin. The relative number of ES cells was determined by
staining with 0.1% crystal violet, extracting cell-associated dye using
10% acetic acid, and measuring absorbance at A590. Results are
presented as mean6SEM. Results represent a single experiment. Similar
results were obtained from three independent experiments.
doi:10.1371/journal.pone.0046256.g005
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ment and are viable and fertile. Thus, under normal conditions in
mice, T166 and the SRJ domain are dispensable for these
functions. We suggest that point mutations and deletions clustering
in the SRJ region may require additional genetic or environmental
factors to cause disease. Our results suggest that coding sequence
mutations observed in case-control studies need validation using in
vivo models and that predictions based on structural conservation
and in vitro functional assays, or even in vivo global loss of function
models, may be insufficient. This has implications for the
interpretation of data arising from exon resequencing programs
currently being pursued in cardiac and other developmental
diseases.
Materials and Methods
Cases and controls
Patients (all of North West European White Caucasian ancestry)
were ascertained through referring clinicians as part of the Genetic
Origins of Congenital Heart Disease Study (GO-CHD) at several
UK paediatric and adult congenital heart disease centres and were
evaluated by physical examination and echocardiography. Sam-
ples were also obtained through collaboration with the University
of Newcastle. Patients with CHD where the genetic mechanism
was known were excluded (Down syndrome and DiGeorge
syndrome amongst others). Ethnicity was determined by ques-
tionnaire and based on all four grandparents using the 2001 UK
census of the population categories. Blood or saliva was collected
from each affected individual and their parents, where available,
and DNA was extracted using standard techniques. Written
informed consent for inclusion in molecular genetic studies was
obtained in each case. Approval for this study was obtained from a
national ethics committee (MREC for Wales, REF 05/MRE09/
89). 1227 unselected control samples were obtained from North
West European White Caucasian individuals from the 1958 UK
birth cohort (1041) and from the Wellcome Trust Case Control
Consortium UK blood donor collection (186).
DNA sequencing
Oligonucleotides were designed from flanking intronic and
exonic sequence of the CITED2 gene (Accession No. AF129290)
to produce two ,500 bp PCR products. The following PCR
primer pairs were used. To amplify the N terminal product:
forward primer: 59 TGTGGCGCGGGTCTCATTATC, reverse
primer: 59 CTGGTTTGTCCCGTTCATCTG; to amplify the C
terminal product: forward primer 59 TCACCCCTACCCCCA-
CAACC, reverse primer 59 TTCACGCCGAAGAAGTTGGG.
Both strands of each product were sequenced on an automated
ABI3730 sequencer using BigDye terminator cycle sequencing
reagents (Applied Biosystems, CA, USA). Chromatographs were
analyzed using PHREDPHRAP, Sequencher (v4.8, Gene Codes
Corp., MI, USA) and GAP4 in house software (Wellcome Trust
Sanger Institute, Cambridge, UK). Parental samples were
analyzed where available to determine inheritance.
Transient transfection and pull-down experiments
Plasmids, transfection conditions for transient transfection exper-
iments, and luciferase assays have been previously described [10,14].
Site directed mutagenesis was performed using the QuikChangeTM
Site-Directed Mutagenesis Kit (Stratagene) as per manufacturer’s
instructions, and oligonucleotides 59-GCGGCGGCAGCAG-
CAACCCGGGCGGCTCGGGCGGC and 59-GCCGCCCGA-
GCCGCCCGGGTTGCTGCTGCCGCCGC were used to create
the T166N mutation which was confirmed by sequencing. GST
pulldown experiments and desferrioxamine treatments were per-
formed as previously described [10]. MAPK1 expression plasmid
was a gift from Ralf Janknecht [52]. MAPKK1, MAPKK1S221A
and MAPKK1-S217ES221E plasmids were gifts from Chris
Marshall [53].
Identification of phosphorylation sites in CITED2
Phosphorylation of CITED2 by active GST-ERK2 was carried
out as described [54]. Wild type human GST-CITED2 (,2 mM)
or mutant GST-CITED2-T166N were incubated for 60 min at
30uC with activated human GST-ERK2 (2 U/ml), 10 mM
magnesium acetate and 1 mM [c32P]ATP (Amersham Bioscience)
in 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM sodium
orthovanadate and 0.1% (v/v) 2-mercaptoethanol. The procedure
for mapping the phosphorylation sites is detailed elsewhere [55].
The 32P-labelled protein was reduced with DTT and incubated
with 0.5% (v/v) iodoacetamide to alkylate cysteine residues and
subjected to SDS-PAGE. The band corresponding to 32P-labeled
GST-CITED2 was excised, digested with trypsin and chromato-
graphed on a Vydac C18 column (218TP5215, 2 mm i.d.
615 cm) equilibrated in 0.1% (v/v) trifluoroacetic acid (TFA).
The column was developed with a gradient of acetonitrile in 0.1%
(v/v) TFA from 0–30% acetonitrile (0–90 min), 30–50% acetoni-
trile (90–110 min) and 50–100% acetonitrile (110–120 min). The
flow rate was 0.2 ml/min, fractions of 0.1 ml were collected and
the 32P radioactivity determined by Cerenkov counting. Briefly,
sites of phosphorylation within the peptides were determined by a
combination of MALDI-TOF and MALDI TOF-TOF (matrix
assisted laser-desorption ionization-time-of-flight/time-of-flight)
mass spectrometry on an Applied Biosystems 4700 TOF/TOF
Proteomics Analyser (utilising 5 mg/ml alpha cyano-cinnamic
acid in 10 mM ammonium phosphate 50% acetonitrile as the
matrix), and solid-phase Edman sequencing of peptides coupled to
a Sequelon-arylamine membrane (on an Applied Biosystems 494C
protein sequencer). The release of 32P radioactivity after each cycle
of Edman degradation was counted. Phosphoaminoacid analysis
was performed as described [54].
Figure 6. Generation of Cited2 alleles. (A) Targeting strategy for the generation of Cited2 T166N allele by homologous recombination. The T to N
change was introduced by site directed mutagenesis into the orthologous residue in the mouse sequence. The structure of the wildtype Cited2 allele,
targeting vector, targeted allele, and its structure after FLP mediated recombination are shown. The open reading frame (ORF, blue arrow) is entirely
contained within exon 2 (exons indicated by grey rectangles). The targeting vector has an frt-PGK-NeoR-frt selection cassette downstream of exon 2,
followed by a DTA (diphtheria toxin) cassette. (B) Targeting strategy for the generation of the Cited2attP ES cell line. A 59 attP site was introduced into
the first intron, upstream of the ATG and a 39 attP site downstream of the stop codon and exon 2 as part of the neomycin selection cassette, in
between the PGK promoter and the neomycin coding region. A DTA cassette was also introduced downstream of the 39 homology arm for negative
selection. (C) The human CITED2MRG1 isoform (not shown) and the human full length CITED2 were targeted into the Cited2 locus via PhiC31 integrase
mediated cassette exchange. The exchange event occurs between the attP and attB sites giving rise to attL and attR sites. Successful exchange
replaces the mouse Cited2 ORF with that of either the MRG1 isoform of CITED2 or the full length human CITED2 and brings the puromycin resistance
gene under control of the PGK promoter.
doi:10.1371/journal.pone.0046256.g006
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Figure 7. Phenotypic analysis of mouse embryos expressing CITED2 variants. MRI analysis of embryos 15.5 days post coitum (dpc).
Genotypes are indicated as shown. Sagittal sections through the left kidney (A–E) are shown to indicate the left adrenal gland where present (arrows),
and absent (arrowhead). Transverse sections through the thorax (F–J) and 3D reconstructions (K–O) are shown to demonstrate cardiac anatomy. Loss
of Cited2 leads to adrenal agenesis (B, arrowhead), right atrial isomerism, ventricular septal defect (VSD) and common atrium (G), and abnormal
ventricular topology (L). Embryos expressing only the T166N variant, the MRG1 isoform, or full length human CITED2 have normal adrenal glands and
hearts. RA, Right Atria; RV, Right Ventricle; LV, Left Ventricle; IVS, Interventricular Septum; IAS, Intra-atrial Septum; AAo, Aorta; AoA, Aortic Arch; Tr,
Trachea; DAo, Dorsal Aorta; LSVS and RSVS, Left and Right Systemic Venous Sinus. Axis: A, Anterior; P, Posterior; V, Ventral; D, Dorsal; L, Left; R, Right.
Scale bars: 0.5 mm.
doi:10.1371/journal.pone.0046256.g007
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ES cell pluripotency
E14/T cells [56] (gift from Austin Smith) were transfected with
pPyCAGIP-CITED2 or CITED2-T166N episomal expression
vectors, pPyCAGIP-Nanog vector (positive control) and empty
vector [36]. Cells were selected with puromycin, and then tested
for maintenance of cell proliferation in the absence of LIF. Cell
proliferation was assayed using crystal violet staining as described
[13].
Generation of Cited2 T166N mice
The T166N mutation was introduced into the endogenous
Cited2 gene by gene targeting in murine 129Sv embryonic stem
(ES) cells (Fig. 6A). The targeting vector was constructed using
Cited2 genomic sequences isolated from a lFIXII-129SvJ genomic
library (Stratagene). The C-A change which converts Threonine
166 to Arginine was introduced via site directed mutagenesis
which also introduced an adjacent, silent PasI restriction site 7 bp
downstream. Further cloning and primer information is available
upon request. The frt-PGK-NeoR-frt selection cassette was inserted
1.581 kb downstream of the stop codon. A DTA cassette was also
introduced downstream of the 39 homology arm for negative
selection. The targeting vector was linearized with NheI and
electroporated into ES cells at GenOway (France). ES cells were
selected in 350 ug/ul G418. Correct targeting of the Cited2 gene at
the 39arm was detected by long range PCR spanning the
homology region and at the 59arm by Southern blotting (data
not shown). Correctly targeted ES cell clones were injected into
C57BL/6J blastocysts and chimeras crossed to C57BL/6J females.
Following successful germline transmission, targeting was con-
firmed to be correct by Southern blotting using standard protocols
(Fig. 8C). Heterozygous mice were crossed to FLPeR [57] mice in
a C57BL/6J background to remove the frt-PGK-NeoR-frt selection
cassette. The resulting FLP recombined Cited2 +/T166N mice were
backcrossed to C57BL/6J for at least 2 further generations prior to
the start of experiments and maintained by backcrossing to
C57BL/6J mice. All studies involving animals were performed in
accordance with UK Home Office Animals (Scientific Procedures)
Act 1986 and approved by the University of Oxford’s Local
Ethical Review Process.
Generation of the Cited2attP ES cell line
The Cited2attP ES cell line was generated via homologous
recombination in C57BL/6N ES cells (Fig. 6B). A targeting
construct was assembled by introducing two PhiC31 integrase attP
sites into the Cited2 locus of genomic DNA isolated from BAC
RP23-450-B12 DNA. The 59 attP site was introduced into the first
intron, upstream of the ATG and the 39 attP site 1.551 kb
downstream of the stop codon as part of the Neomycin selection
cassette, in between the PGK promoter and the Neomycin coding
region. A DTA cassette was also introduced downstream of the 39
homology arm for negative selection. Further details on the
cloning are available upon request. The NotI linearized vector was
electroporated into mouse JM8.F6 ES cells, a C57BL/6N ES cell
line [58], followed by selection in G418 (175 mg/ml). Neomycin
resistant colonies were analyzed by long range PCR spanning both
the 39 and 59 homology arms for correct targeting of the Cited2
gene and integration of the 59 attP site. Primer pairs used for long
range PCR were the following: for the 59 homology arm: forward
primer 59 CCAGGATGGGAAACCCTGACT and reverse
primer 59 CTCAGTTGGGGGCGTAGTTCG, and for the 39
homology arm: forward primer 59 CCCTACCCGGTA-
GAAGTTCCT and reverse primer 59 AGATATCACGTAG-
GATCTGCT. The generated ES cells were validated as being
suitable for subsequence manipulation by injection into albino
C57BL/6J (C57BL/6J-Tyrc-2J/J) blastocysts. Successful germline
transmission was confirmed by the aforementioned long range
PCR. Mice carrying the Cited2 attP allele were bred to homozy-
gosity and in trans to a Cited2 null allele (Cited2 tm1Bha) [11] to ensure
that the tagged Cited2 allele did not disrupt CITED2 function and
to validate the ES cell resource for future manipulation.
Generation of Cited2 MRG1 and Cited2 HUM alleles by
Recombinase Mediated Cassette Exchange (RMCE)
Cited2 MRG1 and Cited2 HUM targeted ES cell lines were generated
via RMCE using the previously targeted Cited2 attP ES cells
(Fig. 6C). Exchange vectors were designed to only replace the
mouse Cited2 ORF with either human full length CITED2 or
CITED2MRG1 ORF, whilst retaining the intact mouse 59 and 39
UTRs. The vectors were assembled by introducing one attB
PhiC31 integrase recognition site upstream of either human full
length CITED2 or MRG1 at the same location in the first intron
where the attP recognition site had previously been inserted. The
second attB site was introduced upstream of the promoterless
puromycin expression cassette. Successful RMCE was thus
designed to reconstitute a functional puromycin resistance cassette.
16106 Cited2 attP ES cells were co-electroporated with 5 mg of
either the full length human CITED2 or the CITED2 MRG1
exchange plasmid and 5 mg of pPhiC31o [59] using the Neon
transfection system (Invitrogen) (361400 V, 10 ms) and plated on
puromycin resistant fibroblast feeder layers. After approximately 7
days of selection in 600 ng/ml puromycin, 24 resistant colonies
were isolated per construct, expanded and screened by PCR for
the correct cassette exchange events at the 59 and 39 ends using
specific primers which amplify across the the resulting attL and attR
sites (to amplify across the attL: forward primer 59 CAG-
CAGGTCCGCCGAGGTAGC and reverse primer 59 AACC-
GAGACCGGTTCAACAGC, and to amplify across the attR:
forward primer 59 CACGCTTCAAAAGCGCACGTCTG and
reverse primer 59 CGCGTGAGGAAGAGTTCTTGCA). The
generation of the attL site was confirmed by digesting the PCR
product with SacII. Correct exchange was further confirmed by
long range PCR (For 59 homology arm: 59 CCAGGATGG-
GAAACCCTGACT and 59 CAGCAGGTCCGCCGAGG-
TAGC, and for the 39 homology arm: 59 CAGAAATCGCAAA-
Table 2. Mice expressing a single copy of the Cited2 T166N (A)
or Cited2 MRG1 (B) allele are found at the expected Mendelian
ratios at weaning.
Expected Observed
Cited2+/2 = X Cited2+/T166NR
Cited2+/T166N 5 5
Cited22/T166N 5 6
Cited2+/+ 5 5
Cited2+/2 5 4
Cited2+/2 = X Cited2+/MRG1 R
Cited2+/MRG1 10.25 10
Cited22/MRG1 10.25 12
Cited2+/+ 10.25 10
Cited2+/2 10.25 9
Mice were genotyped at 3 weeks of age. All genotypes are present at the
expected Mendelian ratios.
doi:10.1371/journal.pone.0046256.t002
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GACGGAAG and 59 AGATATCACGTAGGATCTGCT) fol-
lowed by sequencing of the PCR products.
ES cells from correctly exchanged colonies were injected into
albino C57BL/6J blastocysts. The resulting chimeras were mated
with albino C57BL/6J females. Successful germline transmission
yielded black pups and was confirmed by long range PCR and
Southern blotting for correct targeting and exchange at both 59
and 39 ends. F1 pups were also screened by Southern blotting to
ensure that no ectopic integration of the exchange cassette had
occurred (Fig. 8D). Southern blotting was performed using
standard protocols. Mouse colonies were maintained by back-
crossing to C57BL/6J mice.
Cell Culture
Mouse ES cells were cultured in Knockout DMEM (Dulbecco’s
Modified Eagle Medium, Invitrogen) supplemented with 2 mM L-
Glutamine (PAA), 16non-essential amino acids (PAA), 0.1 mM b-
mercaptoethanol (Sigma), 1000 U/ml ESGRO (Millipore) and
Figure 8. Molecular characterization of the Cited2 T166N, Cited2 MRG1 and Cited2 HUM alleles. (A) Western blot of total protein lysates from
mouse embryonic fibroblasts (MEFs), probed with anti-CITED2 antibody. CITED2 and CITED2-MRG1 are indicated, as is a non-specific band (N.S.) that
migrates at 25 kDa. (B) RT-PCR showing RNA products expressed by embryos of various genotypes. PCR primers were designed to differentiate
between the endogenous mouse Cited2 transcript and the Cited2 MRG1 transcript by their size difference. Wild type mouse Cited2, containing the SRJ
domain produces the larger 725 bp band. (C) Southern blots of Cited2 T166N allele. Top, Southern blot of EcoRI digested genomic DNA probed with a
59-probe. Middle, Southern blot of BglII digested genomic DNA, probed with a 39-probe. Probe positions are indicated in Fig. 3. Bottom, Southern blot
of SpeI digested genomic DNA hybridized with an internal (Neomycin) probe, to confirm single copy integration. (D) Southern blots of Cited2 MRG1 and
Cited2 HUM alleles. Top, Southern blot of EcoRI/SacII digested genomic DNA, probed with a 59-probe. Middle, Southern blot of BglII digested genomic
DNA, probed with a 39-probe. The position of the probes is indicated in Fig. 3. Bottom, Southern blot of EcoRI digested genomic DNA hybridized with
an internal (Puromycin) probe to confirm single copy integration.
doi:10.1371/journal.pone.0046256.g008
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10% fetal bovine serum (Invitrogen). Hep3B cells (ATCC
No. HB-8064) were grown in Minimum Essential Medium
(MEM) supplemented with 2 mM L-glutamine, 1% penicillin-
streptomycin, and 10% FBS. All cells were cultured at 37uC in a
humidified atmosphere containing 5% CO2.
Generation and analysis of embryos
Cited2 +/T166N, Cited2 +/MRG1 and Cited2 +/HUM were crossed to
mice heterozygous for the Cited2 tm1Bha null allele (Cited2 +/2).
Embryos were dissected at 15.5 dpc and harvested and processed
for Magnetic Resonance Imaging (MRI) as previously described
[11]. MRI was performed on a horizontal 9.4 T/21 cm VNMRS
Direct DriveTM MR system (Varian Inc., Palo Alto, CA, USA) as
described previously [60]. Genotype deviation from expected
Mendelian ratios was analysed using the X2 test. The calculated
probability of a type 1 error was calculated using the CHIDIST
function in Excel (Microsoft Office 2007, Microsoft, Redmond,
WA, USA).
Western Blotting
Mouse embryonic fibroblasts (MEFs) isolated using standard
protocols from decapitated and eviscerated 13.5 dpc embryos
were lysed in lysis buffer (50 mM Tris, 150 mM NaCl, 0.5%
Tx100) containing protease inhibitors (cOmplete, EDTA-free
Protease Inhibitor Cocktail, Roche) at 4uC for 20 minutes,
followed by centrifugation and removal of the non-soluble pellet.
Protein concentrations were quantified using the Bicinchoninic
acid (BCA) protein assay kit (Pierce). 60 ug of whole cell lysate
were loaded into each well of a NuPage NOVEX 4–12% Bis-Tris
gel (Invitrogen) and blotted onto a nitrocellulose membrane using
standard protocols. Western blots using Hep3B cells were
processed in a similar manner. Mouse monoclonal antibody
against CITED2 (JA22) was used at 1:500 (Abcam).
RT-PCR
Total RNA was isolated from the caudal half of 13.5 dpc
embryos using the RNeasy Tissue Kit (Qiagen) and first strand
cDNA was synthesized using Quantitect Reverse Transcription
Kit (Qiagen) as per manufacturer’s instructions using 1 ug of total
RNA. 1/20th of the reverse transcription product was used per
PCR reaction. PCR products were gel purified and sequenced to
confirm identity. The following PCR primers were used: forward
primer 59 CAGAAATCGCAAAGACGGAAG and reverse prim-
er 59 CTCGTCGATGAAATCAGTGTC.
Supporting Information
Figure S1 Disorder plot of mouse wild type CITED2 and
variants. RONN (http://www.strubi.ox.ac.uk/RONN) was used
to predict protein disorder. The highest peak, representing the
highest probability of disorder, resides over residues corresponding
to the SRJ (161–199) (red box). The CR2 domain (green box) has
the lowest probability of disorder, consistent with it harboring all
known biological functions of CITED2. CR1 (blue box) and CR3
(purple box) are also marked in the graph for the wild type protein.
The location of the molecular lesions in each variant is indicated
with a black arrow. The location of the SRJ and flanking residues
which have been removed in the MRG1 isoform is marked with
the red arrow.
(TIF)
Figure S2 CITED2 T166N mutation does not impair
CITED2’s ability to repress HIF1 transactivation. (A)
Hep3B cells were transiently cotransfected with GAL4-HIF1A
(40 ng), 3xGAL4-luciferase reporter (100 ng), CMV-lacZ
(100 ng), and increasing amounts (4 and 40 ng) of CITED2 or
mutant plasmids. GAL4-HIF1A transactivation was stimulated by
adding desferrioxamine (DFO, 100 mM) as indicated. Results are
presented as in (Fig. 2). (B) Western blots were performed using
whole cell extracts prepared from Hep3B cells transfected with the
indicated CITED2 plasmids. CITED2 was detected using a
monoclonal anti-CITED2 antibody (top panels). Loading was
monitored by probing the membrane with a monoclonal anti-b-
tubulin antibody (bottom panels). (C, D) Top panels: Autoradio-
grams of gels showing the binding of 35S-labelled CITED2 and
CITED2-p.T166N to GST (lanes 3, 4, 9, 10), GST-TFAP2A
(lanes 5 and 6) and GST-p300CH1 (lanes11–12). Bottom panels:
Coomassie blue stain of the gels showing relative amounts of GST,
GST-TFAP2A and GST-EP300CH1 proteins. (E) Hep3B cells
were transfected with CITED2 plasmids expressing the indicated
CITED2 proteins. These were detected forty-eight hours after
transfection by indirect immunofluorescence, using a monoclonal
anti-CITED2 antibody and a secondary rabbit anti-mouse
antibody coupled to FITC (green). Nuclei were counterstained
with DAPI (blue). The merged image is shown in the panels on the
extreme right.
(TIF)
Figure S3 Co-expression of MAPK1 or MAPKK1 did not
affect the expression of CITED2. Western blot were
performed using whole cell extracts prepared from Hep3B cells
co-transfected with the plasmid expressing CITED2, a plasmid
expressing MAPK1 and with plasmids expressing a kinase inactive
MAPKK1 (SV40-MAPKK1-S221A) or a constitutively active
MAPKK1 (SV40-MAPKK1-S217ES221).
(TIF)
Figure S4 Adrenal gland size measurements. The volume
of adrenal glands of 15.5 dpc embryos were measured by
segmentation analysis using Amira 5.3 (Visage, Berlin). All
measurements were corrected for embryo weight. Values represent
measurements obtained from 6 embryos from each genotype.
Error bars represent SEM.
(TIF)
Figure S5 E15.5 Cited2 2/MRG1 embryo with ectopia
cordis. Single embryo out of 75 of the same genotype to present
with any structural developmental anomaly. (A) External side
view, (B) frontal view and (C) MRI image of sagittal section
through embryo showing the ectopic heart (arrowhead) rostral to
the umbilical hernia (arrow); the left forelimb has been removed.
(D) Sagittal section through left adrenal gland (Ad). (E) Transverse
section through the heart showing the heart outside the chest
cavity and (F) 3D reconstruction of the heart and major vessels
showing normal topology of the right and left ventricles (RV, LV)
and a small ventricular septal defect (VSD). RA, Right Atria; LA,
Left Atria; IVS, intraventricular septum; Tr, Trachea; AoA, Aortic
Arch; DAo, Dorsal Aorta. Scale bars: 0.5 mm.
(TIF)
Text S1
(DOCX)
Table S1 Diagnostic characteristics for all 1126 cases
sequenced. Many patients have multiple diagnoses and
for these the patient is recorded in the diagnostic
category for the lesion most likely to need clinical
intervention. Abbreviations: Transposition of the great arteries
(TGA; cc – congenitally corrected), secundum atrial septal defect
(ASD), Tetralogy of Fallot (TOF), atrioventricular septal defect
(AVSD), ventricular septal defect (VSD), pulmonary atresia with
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intact ventricular septum (PA/IVS), pulmonary atresia with
ventricular septal defect (PA-VSD), coarctation of aorta (CoA),
aortic stenosis (AS), hypoplastic left heart syndrome (HLHS),
mitral valve abnormalities (MV abn), patent ductus arteriosus
(PDA), double outlet right ventricle (DORV), pulmonary stenosis
(PS), common arterial trunk (CAT), aorto-pulmonary (AP)
window, tricuspid atresia (TA), double inlet left ventricle (DILV),
discordant ventriculo-arterial connections (discordant VA) and
partial and total anomalous venous drainage (PAPVD and
TAPVD respectively).
(DOCX)
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